Skip to main content

Advertisement

Table 2 Demographic and baseline characteristics for all randomized patients who entered the 12-week treatment period

From: Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension

Demographic variable All patients
Age, years (n = 93)
 Mean ± SD 21.6 ± 7.7
 Median (min, max) 21.0 (9, 42)
≥18 years of age, n (%) 58 (62.4)
Male, n (%) (n = 93) 64 (68.8)
White, n (%) (n = 93) 88 (94.6)
Height, cm (n = 93)
 Mean ± SD 172.3 ± 11.5
 Median (min, max) 174.1 (134.1, 195.6)
Weight, kg (n = 93)
 Mean ± SD 70.1 ± 17.1
 Median (min, max) (69.8, 117.1)
Time since diagnosis of EoE, monthsa (n = 87)
 Mean ± SD 37.6 ± 38.2
 Median (min, max) 26.3 (−0.1, 164.2)
Physician Global Assessment of disease activity (n = 93)
 Mean ± SD 58.3 ± 21.5
 Median (min, max) 62.0 (0, 94.0)
DSQ score (n = 92)
 Mean ± SD 29.8 ± 14.8
 Median (min, max) 28.0 (6.5, 61.1)
Peak eosinophil count (eos/hpf) Placebo (n = 42) BOS (n = 51)
 Mean ± SD 133.0 ± 81.6 157.8 ± 96.1
  1. BOS budesonide oral suspension, DSQ Dysphagia Symptom Questionnaire, EoE eosinophilic esophagitis, eos eosinophils, hpf high-power field, max maximum, min minimum, SD standard deviation
  2. aDefined as the number of days between the date of diagnosis and the screening visit date